The TSC1-TSC2 complex is required for proper activation of mTOR complex 2.

Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell (2010) 7.61

The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J (2008) 6.32

A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans (2009) 4.37

Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol (2009) 3.32

mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol (2009) 3.22

Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. Cell Metab (2008) 3.22

Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem (2010) 2.90

mTOR complex 2 signaling and functions. Cell Cycle (2011) 2.66

Common corruption of the mTOR signaling network in human tumors. Oncogene (2008) 2.60

mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol (2009) 2.57

Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PLoS One (2009) 2.54

mTORC1-dependent and -independent regulation of stem cell renewal, differentiation, and mobilization. Proc Natl Acad Sci U S A (2008) 2.48

The mTOR signalling pathway in human cancer. Int J Mol Sci (2012) 2.38

mTOR couples cellular nutrient sensing to organismal metabolic homeostasis. Trends Endocrinol Metab (2011) 2.28

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene (2010) 2.22

Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol (2013) 2.22

TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. Mol Cell (2012) 2.22

p62: a versatile multitasker takes on cancer. Trends Biochem Sci (2012) 1.93

mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. J Biol Chem (2009) 1.93

Hierarchical modularity and the evolution of genetic interactomes across species. Mol Cell (2012) 1.88

NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol (2009) 1.78

"Malignant" perivascular epithelioid cell neoplasm: risk stratification and treatment strategies. Sarcoma (2012) 1.75

Ras-mediated activation of the TORC2-PKB pathway is critical for chemotaxis. J Cell Biol (2010) 1.64

Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes Dev (2008) 1.60

Loss of Tsc1 in vivo impairs hippocampal mGluR-LTD and increases excitatory synaptic function. J Neurosci (2011) 1.60

A comprehensive map of the mTOR signaling network. Mol Syst Biol (2010) 1.59

mTOR: on target for novel therapeutic strategies in the nervous system. Trends Mol Med (2012) 1.59

Mammalian target of rapamycin signaling in cardiac physiology and disease. Circ Res (2014) 1.59

Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors. Cancer Res (2009) 1.58

Host metabolism regulates intracellular growth of Trypanosoma cruzi. Cell Host Microbe (2013) 1.57

Regulation of mTORC1 by PI3K signaling. Trends Cell Biol (2015) 1.54

mTORC1 serves ER stress-triggered apoptosis via selective activation of the IRE1-JNK pathway. Cell Death Differ (2011) 1.52

Coordinated regulation of protein synthesis and degradation by mTORC1. Nature (2014) 1.51

Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders. Trends Mol Med (2010) 1.46

The neurology of mTOR. Neuron (2014) 1.43

Activation of lysosomal function in the course of autophagy via mTORC1 suppression and autophagosome-lysosome fusion. Cell Res (2013) 1.42

mTOR signaling for biological control and cancer. J Cell Physiol (2013) 1.40

Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell Cycle (2008) 1.40

Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol Cancer Ther (2011) 1.38

The tuberous sclerosis complex-mammalian target of rapamycin pathway maintains the quiescence and survival of naive T cells. J Immunol (2011) 1.37

From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis. J Intellect Disabil Res (2009) 1.37

mTORC2 is required for proliferation and survival of TSC2-null cells. Mol Cell Biol (2011) 1.36

Interconnections between apoptotic, autophagic and necrotic pathways: implications for cancer therapy development. J Cell Mol Med (2013) 1.36

Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. Oncotarget (2012) 1.34

Regulation of T-cell survival and mitochondrial homeostasis by TSC1. Eur J Immunol (2011) 1.34

Growing knowledge of the mTOR signaling network. Semin Cell Dev Biol (2014) 1.33

Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist (2011) 1.32

TSC1/TSC2 signaling in the CNS. FEBS Lett (2011) 1.31

Amino acids activate mammalian target of rapamycin complex 2 (mTORC2) via PI3K/Akt signaling. J Biol Chem (2010) 1.30

Noncanonical TGF-beta pathways, mTORC1 and Abl, in renal interstitial fibrogenesis. Am J Physiol Renal Physiol (2009) 1.27

PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J Androl (2014) 1.23

Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders. Oxid Med Cell Longev (2010) 1.21

Phosphorylation of AKT: a mutational analysis. Oncotarget (2011) 1.17

TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity. Oncogene (2009) 1.16

Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells. Am J Respir Cell Mol Biol (2009) 1.15

Differential response of skeletal muscles to mTORC1 signaling during atrophy and hypertrophy. Skelet Muscle (2013) 1.14

Enhancing mTOR-targeted cancer therapy. Expert Opin Ther Targets (2009) 1.13

Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin. Prog Neurobiol (2012) 1.13

The Mechanistic Target of Rapamycin: The Grand ConducTOR of Metabolism and Aging. Cell Metab (2016) 1.10

Deletion of Rictor in neural progenitor cells reveals contributions of mTORC2 signaling to tuberous sclerosis complex. Hum Mol Genet (2012) 1.10

Emerging evidence of a link between the polycystins and the mTOR pathways. Pathogenetics (2009) 1.09

Tuberous sclerosis 1 (Tsc1)-dependent metabolic checkpoint controls development of dendritic cells. Proc Natl Acad Sci U S A (2013) 1.08

GABAergic interneuron development and function is modulated by the Tsc1 gene. Cereb Cortex (2011) 1.07

Non-canonical functions of the tuberous sclerosis complex-Rheb signalling axis. EMBO Mol Med (2011) 1.07

mTOR signaling: RAG GTPases transmit the amino acid signal. Trends Biochem Sci (2008) 1.06

Imbalanced mechanistic target of rapamycin C1 and C2 activity in the cerebellum of Angelman syndrome mice impairs motor function. J Neurosci (2015) 1.06

Smooth muscle protein-22-mediated deletion of Tsc1 results in cardiac hypertrophy that is mTORC1-mediated and reversed by rapamycin. Hum Mol Genet (2011) 1.05

Dynamic switch of negative feedback regulation in Drosophila Akt-TOR signaling. PLoS Genet (2010) 1.04

In vivo analysis of protein kinase B (PKB)/Akt regulation in DNA-PKcs-null mice reveals a role for PKB/Akt in DNA damage response and tumorigenesis. J Biol Chem (2008) 1.04

Malignant perivascular epithelioid cell tumor of the uterus. Rare Tumors (2012) 1.01

Regulation of mast cell survival and function by tuberous sclerosis complex 1. Blood (2012) 1.01

Distinct DNA methylation patterns of cognitive impairment and trisomy 21 in Down syndrome. BMC Med Genomics (2013) 1.01

Paired box gene 8-peroxisome proliferator-activated receptor-gamma fusion protein and loss of phosphatase and tensin homolog synergistically cause thyroid hyperplasia in transgenic mice. Endocrinology (2009) 1.00

Loss of the tuberous sclerosis complex protein tuberin causes Purkinje cell degeneration. Neurobiol Dis (2011) 1.00

mTOR: a link from the extracellular milieu to transcriptional regulation of oligodendrocyte development. ASN Neuro (2013) 0.99

Unrestrained mammalian target of rapamycin complexes 1 and 2 increase expression of phosphatase and tensin homolog deleted on chromosome 10 to regulate phosphorylation of Akt kinase. J Biol Chem (2011) 0.99

Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy. Proc Am Thorac Soc (2010) 0.99

Fetal brain mTOR signaling activation in tuberous sclerosis complex. Cereb Cortex (2012) 0.98

Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders. Br J Clin Pharmacol (2015) 0.97

A hypomorphic allele of Tsc2 highlights the role of TSC1/TSC2 in signaling to AKT and models mild human TSC2 alleles. Hum Mol Genet (2009) 0.97

Oncogenes in cell survival and cell death. Cold Spring Harb Perspect Biol (2012) 0.96

Frontier of epilepsy research - mTOR signaling pathway. Exp Mol Med (2011) 0.95

Stabilization of HIF-2α through redox regulation of mTORC2 activation and initiation of mRNA translation. Oncogene (2012) 0.95

Tuberous sclerosis complex 2 (TSC2) regulates cell migration and polarity through activation of CDC42 and RAC1. J Biol Chem (2010) 0.94

Pdk1 activity controls proliferation, survival, and growth of developing pancreatic cells. Dev Biol (2009) 0.93

TSC2 deficiency increases PTEN via HIF1alpha. J Biol Chem (2009) 0.92

Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies. Respir Med (2010) 0.92

Identification of mTORC2 as a necessary component of HRG/ErbB2-dependent cellular transformation. Mol Cancer Res (2014) 0.89

Regulation of the mTOR signaling pathway: from laboratory bench to bedside and back again. F1000 Biol Rep (2009) 0.89

Jejunal proteins secreted by db/db mice or insulin-resistant humans impair the insulin signaling and determine insulin resistance. PLoS One (2013) 0.88

mTOR and lysosome regulation. F1000Prime Rep (2014) 0.88

The role and regulation of mTOR in T-lymphocyte function. Arch Immunol Ther Exp (Warsz) (2012) 0.88

Critical role of SCD1 in autophagy regulation via lipogenesis and lipid rafts-coupled AKT-FOXO1 signaling pathway. Autophagy (2013) 0.88

A shower of second hit events as the cause of multifocal renal cell carcinoma in tuberous sclerosis complex. Hum Mol Genet (2014) 0.87

Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning Conference. Pediatr Neurol (2016) 0.87

Constitutive Activation of mTORC1 in Endothelial Cells Leads to the Development and Progression of Lymphangiosarcoma through VEGF Autocrine Signaling. Cancer Cell (2015) 0.87

Lymphangioleiomyomatosis and TSC2-/- cells. Lymphat Res Biol (2010) 0.87

AKT/PKB Signaling: Navigating the Network. Cell (2017) 0.87

Regulation of blood-testis barrier (BTB) dynamics during spermatogenesis via the "Yin" and "Yang" effects of mammalian target of rapamycin complex 1 (mTORC1) and mTORC2. Int Rev Cell Mol Biol (2013) 0.86

Sestrin 3 protein enhances hepatic insulin sensitivity by direct activation of the mTORC2-Akt signaling. Diabetes (2014) 0.86

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99

TOR signaling in growth and metabolism. Cell (2006) 35.29

AKT/PKB signaling: navigating downstream. Cell (2007) 31.26

Defining the role of mTOR in cancer. Cancer Cell (2007) 21.63

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 18.36

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell (2002) 18.22

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol (2004) 16.83

Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J (1996) 16.68

The tuberous sclerosis complex. N Engl J Med (2006) 13.53

Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature (2004) 12.36

Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell (2002) 11.65

Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell (2002) 11.59

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell (2002) 11.50

Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell (2006) 11.48

SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell (2006) 10.50

The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol (2004) 9.71

PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell (2007) 9.68

Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev (2003) 9.58

Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol (2003) 8.25

Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol (2004) 7.59

Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet (2005) 7.15

A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet (2002) 7.12

Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell (2003) 6.76

mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell (2005) 6.71

Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol (2003) 6.32

The two TORCs and Akt. Dev Cell (2007) 6.17

Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest (2003) 6.04

mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem (2005) 5.62

Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol (2002) 5.37

GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell (2003) 5.21

Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev Cell (2006) 5.19

mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol (2006) 5.06

Rheb promotes cell growth as a component of the insulin/TOR signalling network. Nat Cell Biol (2003) 5.01

Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev (2006) 4.78

Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res (2005) 4.74

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol (2004) 4.70

mTOR, translation initiation and cancer. Oncogene (2006) 4.68

Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A (2000) 4.30

Rheb is an essential regulator of S6K in controlling cell growth in Drosophila. Nat Cell Biol (2003) 4.20

The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem (2003) 3.83

Identification of a conserved motif required for mTOR signaling. Curr Biol (2002) 3.78

The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A (2005) 3.72

Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol Cell Biol (2006) 3.67

PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest (2007) 3.54

S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol Cell (2006) 3.25

Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev (2005) 3.25

Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem J (2007) 3.08

Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency. J Biol Chem (2005) 2.70

Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2. Proc Natl Acad Sci U S A (2006) 2.41

PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling. J Biol Chem (2007) 2.25

The in vivo role of PtdIns(3,4,5)P3 binding to PDK1 PH domain defined by knockin mutation. EMBO J (2004) 2.11

TSC1/TSC2 and Rheb have different effects on TORC1 and TORC2 activity. Proc Natl Acad Sci U S A (2006) 2.06

Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms. Hum Pathol (2007) 1.99

The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene (2000) 1.89

TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase. J Biol Chem (2006) 1.85

Turnover of the active fraction of IRS1 involves raptor-mTOR- and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosis. Mol Cell Biol (2006) 1.82

Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol (2003) 8.25

The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell (2004) 7.77

Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell (2010) 7.61

Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev (2004) 7.51

Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell (2003) 7.42

The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J (2008) 6.32

Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A (2002) 4.93

A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans (2009) 4.37

Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genet (2005) 3.94

Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol Cell (2008) 3.91

Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol (2009) 3.32

S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol Cell (2006) 3.25

Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat Cell Biol (2013) 3.11

Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metab (2011) 2.91

Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science (2013) 2.90

Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov (2011) 2.77

Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PLoS One (2009) 2.54

Hedgehog signaling promotes prostate xenograft tumor growth. Endocrinology (2004) 2.47

mTOR couples cellular nutrient sensing to organismal metabolic homeostasis. Trends Endocrinol Metab (2011) 2.28

TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. Mol Cell (2012) 2.22

Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell (2011) 2.17

NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol (2009) 1.78

Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis. Nat Cell Biol (2013) 1.73

The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell (2006) 1.63

Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors. Cancer Res (2009) 1.58

The TSC-mTOR pathway regulates macrophage polarization. Nat Commun (2013) 1.57

mTOR links oncogenic signaling to tumor cell metabolism. J Mol Med (Berl) (2011) 1.55

Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice. Sci Signal (2012) 1.50

Transcriptional control of cellular metabolism by mTOR signaling. Cancer Res (2011) 1.44

A growing role for mTOR in promoting anabolic metabolism. Biochem Soc Trans (2013) 1.37

Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov (2013) 1.27

The multifaceted role of mTORC1 in the control of lipid metabolism. EMBO Rep (2012) 1.16

Induction of cytoplasmic accumulation of p53: a mechanism for low levels of arsenic exposure to predispose cells for malignant transformation. Cancer Res (2008) 1.02

mTORC1 status dictates tumor response to targeted therapeutics. Sci Signal (2013) 0.95

Therapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (TSC). PLoS One (2012) 0.93

n-3 fatty acids reduce arterial LDL-cholesterol delivery and arterial lipoprotein lipase levels and lipase distribution. Arterioscler Thromb Vasc Biol (2009) 0.91

mTORC1 signaling activates NRF1 to increase cellular proteasome levels. Cell Cycle (2015) 0.89

Molecular basis of giant cells in tuberous sclerosis complex. N Engl J Med (2014) 0.87

The mammalian target of rapamycin complex 1 regulates leptin biosynthesis in adipocytes at the level of translation: the role of the 5'-untranslated region in the expression of leptin messenger ribonucleic acid. Mol Endocrinol (2008) 0.87

A molecular link between AKT regulation and chemotherapeutic response. Cancer Cell (2009) 0.87

Chewing the fat on tumor cell metabolism. Cell (2010) 0.86

Phosphatidylcholine transfer protein interacts with thioesterase superfamily member 2 to attenuate insulin signaling. Sci Signal (2013) 0.85

Cell signalling: nutrient sensing lost in cancer. Nature (2013) 0.83

Comment on "A dynamic network model of mTOR signaling reveals TSC-independent mTORC2 regulation": building a model of the mTOR signaling network with a potentially faulty tool. Sci Signal (2012) 0.82

Role of proline residues in conferring thermostability on aqualysin I. J Biochem (2006) 0.81

Correction: Comparison of Bone Mineral Density between Urban and Rural Areas: Systematic Review and Meta-Analysis. PLoS One (2015) 0.75

Three-dimensional CT image analysis of the digging system in the aardvark. Ann Anat (2003) 0.75

Corrigendum: Splicing factor 1 modulates dietary restriction and TORC1 pathway longevity in C. elegans. Nature (2017) 0.75

Functional morphology of the mastication muscles in the lesser and greater mouse deer. J Vet Med Sci (2002) 0.75